Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Minerva Neurosciences (NASDAQ:NERV) had its price target lowered by analysts at HC Wainwright from $5.00 to $4.00. They now have a "neutral" rating on the stock.
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates [Yahoo! Finance]